Background: To report the clinical and epidemiological characteristics of hepatocellular carcinoma (HCC) diagnosed in a cohort of human immunodeficiency virus (HIV)-infected patients in Spain.
Methods: All HIV-infected patients diagnosed of HCC in 18 hospitals in Spain before 31 December 2010 were included. The main characteristics of HCC cases are described and comparisons between cases according to the year of diagnosis are presented.
Results: Eighty-two cases of HCC in HIV-infected patients were included, all of them related to viral hepatitis coinfection: hepatitis C virus (HCV) in 66 (81%), hepatitis B virus (HBV) in 6 (7%), and HBV/HCV in 10 (12%). From 1999, when the first case of HCC was diagnosed, a progressive increment in the incidence of HCC in the cohort has occurred. In patients coinfected with HIV/HCV-coinfected patients, the incidence HCC increased from 0.2 to 2.8 cases per 1000 person-years between 2000 and 2009. Death occurred in 65 patients (79%), with a median survival of 91 days (interquartile range, 31-227 days). Three of 11 patients (28%) who received potentially curative therapy died, compared with 62 of 71 patients (87%) who did not receive curative therapy (P = .0001). Compared with cases of HCC diagnosed before 2005, cases diagnosed later did not show a higher survival rate.
Conclusions: HCC is an emerging complication of cirrhosis in HIV-infected patients. A sharp increase in its incidence has occurred in those also infected by HCV in the recent years. Unfortunately, HCC is frequently diagnosed at an advanced stage, and mortality continues to be very high, with no significant changes in recent years. Earlier diagnosis, which may allow potentially curative therapy, is necessary.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/cid/cis777 | DOI Listing |
Trop Med Infect Dis
December 2024
Department of Parasitology, Mycology and Tropical Medicine, Université des Sciences de la Santé (USS), Libreville BP 4009, Gabon.
Cryptococcal meningitis is a major cause of death in HIV/AIDS patients due to the existence of in the central nervous system. Our objective was to evaluate the prevalence of Cryptococcus antigenuria in a population of HIV-infected patients in Libreville, Gabon. : This study was conducted from April to October 2021 at the Infectious Diseases ward of the Centre Hospitalier Universitaire de Libreville.
View Article and Find Full Text PDFFront Cell Infect Microbiol
December 2024
Department of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Objective: The aim of this study was to assess the clinical value of metagenomic next-generation sequencing (mNGS) of blood samples for the identification of disseminated tuberculosis (DTB).
Methods: A total of 48 individuals suspected of DTB were enrolled. All patients underwent mNGS of peripheral blood and conventional microbiological tests.
Khirurgiia (Mosk)
December 2024
Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.
Objective: To evaluate the effectiveness of leukocyte, NLR, procalcitonin and C-reactive protein as the markers of acute peritonitis in patients with HIV-infection.
Material And Methods: The study included 83 HIV-infected patients with various diseases complicated by acute peritonitis. Leukocytes, procalcitonin and C-reactive protein, as well as immune status and viral load were determined in peripheral blood before surgery.
Cell Mol Biol (Noisy-le-grand)
November 2024
Pietro Annigoni Biomolecular Research Centre (CERBA), Ouagadougou, Burkina Faso.
HIV-2 infection although less virulent compared to HIV-1 is endemic in many parts of West Africa. In Burkina Faso, few data exist on HIV-2 genotypic resistance. The objective of this study was to assess HIV-2 genotypic resistance and viral load in adult patients infected with HIV-2 in Burkina Faso.
View Article and Find Full Text PDFFront Microbiol
November 2024
Department of Animal Science, University of Nebraska-Lincoln, Lincoln, NE, United States.
Introduction: The full extent of interactions between human immunodeficiency virus (HIV) infection, injection drug use, and the human microbiome is unclear. In this study, we examined the microbiomes of HIV-positive and HIV-negative individuals, both drug-injecting and non-injecting, to identify bacterial community changes in response to HIV and drug use. We utilized a well-established cohort of people who inject drugs in Puerto Rico, a region with historically high levels of injection drug use and an HIV incidence rate disproportionately associated with drug use.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!